Publications by authors named "M Heslinga"
Objectives: To estimate the 10-year cardiovascular disease (CVD) risk in gout patients in secondary care and to evaluate the effect of CVD risk screening on the 10-year CVD risk after 1 year.
Methods: A prospective cohort study was performed in patients with gout from Reade Amsterdam. Data on gout and CVD history, traditional risk factors, medication, and lifestyle were collected at baseline and 1 year.
Article Synopsis
- Anti-TNF therapies are used to treat patients with inflammatory rheumatic diseases like ankylosing spondylitis (AS) and may impact cardiovascular health positively.
- A study analyzed the renal function of 211 AS patients treated with anti-TNF, measuring changes in estimated glomerular filtration rate (eGFR) over time.
- Results indicated a slight decline in eGFR, but it was not clinically significant, and anti-TNF treatment was deemed safe for kidney function in AS patients, regardless of pre-existing renal risk factors.
Objective: Several biomarkers of cardiovascular function are found to be increased in rheumatoid arthritis (RA), with some suggesting a relationship with disease activity and improvement with adequate anti-rheumatic treatment. Promising biomarkers include N-terminal pro-brain natriuretic peptide (NT-proBNP) and the soluble receptor form of advanced glycation end-products (sRAGE). The objective of this study was to investigate associations between NT-proBNP and sRAGE levels and markers of inflammation and disease activity in early RA patients and their changes during (effective) anti-rheumatic treatment.
View Article and Find Full Text PDF: Autoimmune thyroid disease often coexists with rheumatoid arthritis (RA) and is associated with elevated cardiovascular (CV) risk. However, studies in RA patients are scarce. Our aim was to investigate whether autoimmune thyroid disease increases the risk of new cardiovascular disease (CVD) in RA.
View Article and Find Full Text PDF